Although circulating tumor DNA (ctDNA) tests are already marketed for this use, they provide no advantage over standard approaches, concludes a new review.
Half of patients treated with combination immunotherapy were still alive after 6.5 years, representing the longest overall survival observed in a phase 3 trial of advanced melanoma.
Stereotactic body radiotherapy (SBRT) significantly improved progression- free survival for patients with oligoprogressive, metastatic lung cancer but not breast cancer.